Search
Diisopromine
go.drugbank.com/drugs/DB13476ExperimentalCategories: Drugs for Functional Gastrointestinal DisordersOleic monoethanolamide
go.drugbank.com/drugs/DB16495InvestigationalCategories: Experimental Unapproved Treatments for COVID-19Azintuxizumab vedotin
go.drugbank.com/drugs/DB14847InvestigationalHas Come Back or Had No Response to Recent Cancer Treatment). … Azintuxizumab vedotin is under investigation in clinical trial NCT02951117 (A Study of Venetoclax and ABBV-838 Combination Therapy With Dexamethasone in Participants With Multiple Myeloma Whose Cancer
FT-1101
go.drugbank.com/drugs/DB17553Investigational[A257301] FT-1101 is under investigation in clinical trial NCT02543879 (Study of a Novel BET Inhibitor FT-1101 in Patients With Relapsed or Refractory Hematologic Malignancies). … FT-1101 is a novel Bromodomain and Extra-Terminal motif (BET) inhibitor.
Zotiraciclib
go.drugbank.com/drugs/DB16656InvestigationalZotiraciclib is under investigation in clinical trial NCT02942264 (Zotiraciclib (TG02) Plus Dose-dense or Metronomic Temozolomide Followed by Randomized Phase II Trial of Zotiraciclib (TG02) Plus Temozolomide
SAR-260301
go.drugbank.com/drugs/DB33608InvestigationalCategories: Class Ia Phosphatidylinositol 3-Kinase, antagonists & inhibitorsFT516
go.drugbank.com/drugs/DB15732InvestigationalIt is also a potential therapy for COVID-19. … This compound expresses a high-affinity 158V, CD16 (hnCD16) Fc receptor that has an enhanced binding ability to tumor-targeting antibodies, and is resistant to downregulation.
Nizubaglustat
go.drugbank.com/drugs/DB21603InvestigationalC Disease, GM1 Gangliosidosis or GM2 Gangliosidosis). … Nizubaglustat has a monoisotopic molecular weight of 433.23 Da.
Mitonafide
go.drugbank.com/drugs/DB19492ExperimentalMitonafide is a small molecule drug. Mitonafide has a monoisotopic molecular weight of 313.11 Da.
Categories: Compounds used in a research, industrial, or household settingNorethandrolone
go.drugbank.com/drugs/DB12787InvestigationalNorethandrolone is under investigation in clinical trial NCT00700544 (Treatment Outcome in Elderly Patients).
Categories: Anabolic Agents for Systemic Use